BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 25597314)

  • 1. Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination.
    van Beek JJ; Wimmers F; Hato SV; de Vries IJ; Sköld AE
    Crit Rev Immunol; 2014; 34(6):517-36. PubMed ID: 25597314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
    Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
    Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells.
    Van Acker HH; Beretta O; Anguille S; De Caluwé L; Papagna A; Van den Bergh JM; Willemen Y; Goossens H; Berneman ZN; Van Tendeloo VF; Smits EL; Foti M; Lion E
    Oncotarget; 2017 Feb; 8(8):13652-13665. PubMed ID: 28099143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
    Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A
    Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third generation dendritic cell vaccines for tumor immunotherapy.
    Frankenberger B; Schendel DJ
    Eur J Cell Biol; 2012 Jan; 91(1):53-8. PubMed ID: 21439674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.
    Hömberg N; Adam C; Riedel T; Brenner C; Flatley A; Röcken M; Mocikat R
    Int J Cancer; 2014 Dec; 135(12):2825-33. PubMed ID: 24771135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.
    Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM
    Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity.
    Vo MC; Lee HJ; Kim JS; Hoang MD; Choi NR; Rhee JH; Lakshmanan VK; Shin SJ; Lee JJ
    Oncotarget; 2015 Oct; 6(32):33781-90. PubMed ID: 26418952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge.
    Bouwer AL; Saunderson SC; Caldwell FJ; Damani TT; Pelham SJ; Dunn AC; Jack RW; Stoitzner P; McLellan AD
    J Immunol; 2014 Mar; 192(5):2514-21. PubMed ID: 24477907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions.
    Willemen Y; Van den Bergh JM; Lion E; Anguille S; Roelandts VA; Van Acker HH; Heynderickx SD; Stein BM; Peeters M; Figdor CG; Van Tendeloo VF; de Vries IJ; Adema GJ; Berneman ZN; Smits EL
    Cancer Immunol Immunother; 2015 Jul; 64(7):831-42. PubMed ID: 25863943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
    Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
    Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction.
    Adam C; King S; Allgeier T; Braumüller H; Lüking C; Mysliwietz J; Kriegeskorte A; Busch DH; Röcken M; Mocikat R
    Blood; 2005 Jul; 106(1):338-44. PubMed ID: 15769894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model.
    Vo MC; Nguyen-Pham TN; Lee HJ; Jaya Lakshmi T; Yang S; Jung SH; Kim HJ; Lee JJ
    Oncotarget; 2017 Apr; 8(16):27252-27262. PubMed ID: 28460478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
    Aravindaram K; Wang PH; Yin SY; Yang NS
    Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 'kiss of death' by dendritic cells to cancer cells.
    Chan CW; Housseau F
    Cell Death Differ; 2008 Jan; 15(1):58-69. PubMed ID: 17948029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
    J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines.
    Petersen TR; Sika-Paotonu D; Knight DA; Simkins HM; Hermans IF
    PLoS One; 2011 Mar; 6(3):e17657. PubMed ID: 21483862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.